OC
MYGN icon

Oppenheimer & Co’s Myriad Genetics MYGN Stock Holding History

Oppenheimer & Co’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-16,910
Closed -$150K – 1667
2025
Q1 		$150K Hold
16,910
– – ﹤0.01% 1488
2024
Q4 		$232K Sell
16,910
-1,156
-6% -$21.3K ﹤0.01% 1395
2024
Q3 		$495K Hold
18,066
– – 0.01% 1032
2024
Q2 		$442K Buy
18,066
+2,878
+19% +$63.1K 0.01% 1040
2024
Q1 		$324K Hold
15,188
– – 0.01% 1151
2023
Q4 		$291K Sell
15,188
-441
-3% -$7.63K 0.01% 1154
2023
Q3 		$251K Sell
15,629
-9
-0.1% -$171 0.01% 1189
2023
Q2 		$362K Sell
15,638
-42
-0.3% -$917 0.01% 1093
2023
Q1 		$364K Buy
+15,680
New +$318K 0.01% 1068
2017
Q4 		– Sell
-40,850
Closed -$1.48M – 1341
2017
Q3 		$1.48M Sell
40,850
-250
-0.6% -$7.13K 0.04% 473
2017
Q2 		$1.06M Sell
41,100
-3,650
-8% -$77.5K 0.03% 578
2017
Q1 		$859K Buy
44,750
+8,900
+25% +$158K 0.02% 629
2016
Q4 		$598K Buy
+35,850
New +$649K 0.02% 747
2015
Q4 		– Sell
-12,401
Closed -$465K – 1339
2015
Q3 		$465K Sell
12,401
-350
-3% -$12.4K 0.01% 833
2015
Q2 		$433K Sell
12,751
-700
-5% -$23.8K 0.01% 947
2015
Q1 		$476K Sell
13,451
-150
-1% -$5.37K 0.01% 887
2014
Q4 		$463K Sell
13,601
-3,836
-22% -$136K 0.01% 856
2014
Q3 		$673K Sell
17,437
-17,069
-49% -$637K 0.02% 742
2014
Q2 		$1.34M Buy
34,506
+2,396
+7% +$89.1K 0.04% 511
2014
Q1 		$1.1M Sell
32,110
-1,878
-6% -$58.2K 0.03% 565
2013
Q4 		$713K Buy
33,988
+24,413
+255% +$617K 0.02% 693
2013
Q3 		$225K Buy
+9,575
New +$272K 0.01% 1100

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Oppenheimer & Co's MYGN Position: Q2 2025 in Review

Oppenheimer & Co sold out of Myriad Genetics (MYGN) in Q2 2025, closing a stake of 16,910 shares — an estimated $150K sold.

Oppenheimer & Co first reported a position in MYGN in Q3 2013 and held it in 22 quarters. The position peaked at $1.48M in Q3 2017. 221 funds tracked by Wall St. Rank hold MYGN as of Q2 2025.

  • Oppenheimer & Co reported no remaining Myriad Genetics position as of Q2 2025 after selling out during the quarter.
  • Oppenheimer & Co sold 16,910 Myriad Genetics shares in Q2 2025, an estimated $150K.
  • Oppenheimer & Co first reported a position in Myriad Genetics in Q3 2013 and held it in 22 quarters.
  • Oppenheimer & Co's Myriad Genetics position peaked at $1.48M in Q3 2017.
  • 221 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2025.

Based on Oppenheimer & Co's 13F filing for Q2 2025, filed 31 Jul 2025.